The gene therapy developer has boosted its initial public offering, which gave an exit to Alexandria Real Estate Equities, to more than $163m in size.

Stoke Therapeutics, a genetic disease therapy developer backed by life sciences real estate developer Alexandria Real Estate Equities, closed its initial public offering at just over $163m on Friday. The offering initially raised about $142m when Stoke priced its shares at $18.00 on Wednesday last week. However, its share price closed at $26.00 on Thursday…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.